Posted by Michael Wonder on 22 Aug 2024
ICER publishes final evidence report on treatment for anaemia in myelodysplastic syndrome
22 August 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate net health benefits for imetelstat added to best supportive care when compared to best supportive care alone; treatment would meet common thresholds of cost effectiveness if priced between $94,800 - $113,000/year, therapy currently priced at approximately $365,000/ year.
The ICER today released a Final Evidence Report assessing the comparative clinical effectiveness and value of imetelstat (Rytelo, Geron Corporation) for the treatment of anaemia in patients with low-to-intermediate risk myelodysplastic syndrome.
